BEIJING — Animal tests of a Chinese COVID-19 vaccine candidate have shown that it can trigger robust neutralizing antibodies against novel coronavirus, a peer-reviewed study has said.
Accordin to the study published on the medical journal Cell, ARCoV, a messenger RNA vaccine by China, induces “neutralizing antibodies and T-cell immunity” in mice and non-human primates.
“ARCoV vaccination confers full protection against SARS-CoV-2 challenge in mice,” it added, referring to the virus that causes COVID-19.
The study also called ARCoV “a promising COVID-19 vaccine candidate with universal availability and global accessibility.”
